Jazeta Novum

Sitagliptin phosphate monohydrate, the active ingredient in Jazeta Novum, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Jazeta Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jazeta Novum, a DPP‑4 inhibitor, is used to improve glycaemic control in patients with type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose when combined with diet and exercise. - Monotherapy for type 2 diabetes: provides glucose reduction as a single oral agent. - Combination therapy for type 2 diabetes: enhances glycaemic control when added to metformin or other antidiabetic agents.

Adverse reactions reported with sitagliptin are generally mild to moderate.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient cranial discomfort of varying intensity. - Upper respiratory tract infection: symptoms such as cough, sore throat, and congestion. - Diarrhoea: loose, watery stools occurring intermittently. - Nausea: feeling of unease and urge to vomit.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with possible vomiting, requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain (arthralgia): persistent or worsening musculoskeletal discomfort. - Bullous pemphigoid: blistering skin disorder that may need specialist care.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Renal impairment: assess kidney function; dose adjustment may be required. - Hepatic impairment: use with caution in patients with liver disease. - History of pancreatitis: avoid use due to increased risk of recurrence. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Concomitant insulin or sulfonylureas: monitor blood glucose closely to prevent hypoglycaemia. - Store at room temperature: keep in the original container, protect from moisture and excessive heat.

Sitagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise plasma concentrations. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glucose homeostasis; monitor blood sugar. - Warfarin: potential alteration of INR; regular coagulation testing advised. - Rifampin: may reduce sitagliptin effectiveness by inducing metabolism.